Zentalis Appoints Shannon Campbell and Sarah Kelly to Build Commercial Infrastructure for Azenosertib Launch

With a registrational Phase 2 and Phase 3 program advancing for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer, Zentalis Pharmaceuticals is now assembling the commercial and companion diagnostic infrastructure that typically precedes a pre-BLA organizational build. The dual appointments of Shannon Campbell to the Board of Directors and Sarah Kelly as SVP of Commercial Strategy signal that supply chain, manufacturing scale-up, and biomarker-aligned market access planning are moving from background activity to active workstreams.

Campbell brings more than 30 years of oncology commercialization experience, most recently as EVP and Chief Commercial Officer at Merus, where she led launch preparedness for a portfolio of multiclonic antibodies. Prior roles at Novartis Pharmaceuticals and Bayer Healthcare Pharmaceuticals covered solid tumor and rare disease launches. She also holds a board seat at Black Diamond Therapeutics and serves on the advisory board of Verix, providing Zentalis with a director who has navigated the clinical-to-commercial transition at multiple oncology organizations.

Kelly's appointment carries particular weight for QA and regulatory leads tracking companion diagnostic integration. Her 30-year career spans commercial and business development roles at Amgen, Turning Point, Spectrum, and Agilent, with explicit focus on building launch organizations for both therapeutics and companion diagnostics. For a biomarker-driven program like azenosertib, where patient selection depends on Cyclin E1 expression, coordinating diagnostic supply, assay validation, and labeling strategy alongside the therapeutic NDA pathway represents a distinct operational challenge that Kelly's profile is structured to address.

CEO Julie Eastland framed the hires as providing the strategic, operational, and commercial foundation for launch readiness and long-term growth, with azenosertib also being evaluated in earlier lines of ovarian cancer, as a combination therapy, and in additional tumor types. That pipeline breadth adds complexity to manufacturing capacity planning and process validation timelines that plant heads will need to track as the registrational program matures.

The measurable checkpoint ahead is the readout from the registrational Phase 3 trial, which will determine whether the commercial infrastructure now being built translates into a formal submission timeline.

Source: Zentalis Pharmaceuticals via GlobeNewswire, May 27, 2026.